Glucagon-like peptide-1 (GLP-1) and fructo-oligosaccharides (FOS) are two distinct yet complementary agents that play important roles in metabolic health. GLP-1 is an incretin hormone involved in glucose regulation and appetite control, whereas FOSs are prebiotic fibres that promote gut health and influence several metabolic processes.
Demand for GLP-1 receptor agonists such as Ozempic and Wegovy has been soaring globally and, with this movement, a plethora of opportunities has opened up for the nutraceutical industry. Many businesses in this sector are now developing new ways to target the side-effects of these drugs as well as identifying natural ingredients that can be taken alongside GLP-1 medications to further support GLP-1 release.
FOSs are currently attracting a lot of attention in this market as a growing body of research has revealed their potential both as a prebiotic and a natural GLP-1 receptor agonist. Therefore, Dr Jacob Hanzon, Head of R&D at Galam, believes that FOS supplementation could be a
revolutionary aid for those taking anti-obesity medications (AOMs).
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.